Pfizer Corporation

Other

Osi Pharmaceuticals, Inc.

Pfizer Products Inc.

Samit Kumar Bhattacharya

John Charles Kath

Joel Morris

Michael Luzzio

Kevin Daniel Freeman-Cook

Jun Xiao

Kendra Louise Nelson

Matthew Merrill Hayward

Kevin James Filipski

Norma Jacqueline Tom

Eric David Cox

Christopher Lowell Autry

Xumiao Zhao

Catherine Angela Hulford

Kimberly O Cameron

Dilinie Fernando

Kimberly O'keefe Cameron

Dilinie Prasadhini Fernando

David Andrew Griffith

Meihua Mike Tu

Matthew Scott Dowling

Yuan Zhang

Bethany Lyn Kormos

Aaron Smith

Matthew Richard Reese

Daniel W Kung

Zhengyu Liu

Luis Angel Martinez-Alsina

Leanne Marie Buzon

Rachel Jane Roth Flach

David Christopher Ebner

Russell Alan Miller

Esther Cheng Lee

Robert Steven Kania

Cynthia Louise Palmer

Christopher Ryan Butler

Richard D Connell

Sajiv Krishnan Nair

Liying Zhang

Kim F McClure

Eugene Yuanjin Rui

Mehran Jalaie

Ping Chen

John M Curto

Martin Youngjin Pettersson

Brian Kenneth Raymer

Donn G Wishka

David James Edmonds

Daniel Wei-Shung Kung

Esther Cheng Yin Lee

Matthew Forrest Sammons

Allyn T Londregan

Goss S Kauffman

Qingyi Yang

Jinshan Michael Chen

Douglas Carl Behenna

Yajing Lian

Esther C Lee

Donn Gregory Wishka

Kimberly O'Keefe Cameron

James Alfred Southers, Jr

Joel Thomas Arcari

Blaise S Lippa

Suvi T M Simila

Gonghua Pan

Arthur Douglas Brosius

Allyn Timothy Londregan

Kim Francis Mcclure

Suvi Tuula Simila

Kiyoyuki Omoto

James Alfred Southers

Suvi Tuula Marjukka Simila

Described herein are compounds of Formula I, wherein R, R, and Rare defined herein, their use as branched-chain alpha keto acid dehydrogenase kinase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetes, NASH and heart failure.

BCKDK inhibitors

This invention relates to compounds of general Formula I in which A, R, R, Rand Rare as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Anti-proliferative agents for treating PAH

The present invention relates to a compound of the formula I wherein Rto R, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Sulfonyl amide derivatives for the treatment of abnormal cell growth

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK. 

Indole and indazole compounds that activate AMPK

The present invention relates to indole and indazole compounds of Formula (I) that activate 5' adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R, R, Ra, L, Z, Zand Zare as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R, R, R, A, K, M, L, L, X, Y, Y, Q, salt thereof, wherein R, R, R, A, K, L, L, W, X, Z, Z, Y, Y, Z, Z, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Pyrimidine derivatives for the treatment of abnormal cell growth

The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R, R, R, R, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

Substituted heterocylces for the treatment of abnormal cell growth

The invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R, R, R, R, R, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

Substituted bicyclic derivatives for the treatment of abnormal cell growth

The invention relates to 6- or 7-bicyclic-substituted 4-amino-subsituted pyridopyrimidines and to pharmaceutically acceptable salts, prodrugs and hydrates thereof. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating hyperproliferative disorders abnormal cell growth in a mammal by administering the compounds.

Bicyclic-substituted 4-amino-pyridopyrimidine derivatives

The invention relates to compounds of the formula 1and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R, R, R, R, R, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

Growing community of inventors

Groton, CT, United States of America

Samit Kumar Bhattacharya